IL17A and Stroke: Stroke risk was significantly lower with IL-17 inhibitors than with IL-23 inhibitors (aHR 0.23; 95% CI, 0.06–0.90) but higher with IL-23 inhibitors than with IL-12/23 inhibitors (aHR 3.71; 95% CI, 1.05–13.11).